Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
/ 2 items
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.